MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course
of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and
biochemical and imaging biomarkers of cartilage degradation. This study will specifically
target older ACL reconstruction patients with concomitant meniscal injuries as this group is
at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive
oral montelukast (10 mg) versus placebo daily for 6 months after surgery.
Phase:
Early Phase 1
Details
Lead Sponsor:
Cale Jacobs, PhD University of Kentucky
Collaborators:
Duke University The Cleveland Clinic University of California, San Francisco